Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash & Equivalents (2016 - 2025)

Sutro Biopharma's Cash & Equivalents history spans 10 years, with the latest figure at $65.9 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 62.24% year-over-year to $65.9 million; the TTM value through Sep 2025 reached $65.9 million, down 62.24%, while the annual FY2024 figure was $190.3 million, 174.74% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $65.9 million at Sutro Biopharma, up from $64.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $235.1 million in Q2 2023 and bottomed at $28.9 million in Q1 2022.
  • The 5-year median for Cash & Equivalents is $65.9 million (2025), against an average of $85.8 million.
  • The largest annual shift saw Cash & Equivalents plummeted 85.25% in 2021 before it surged 215.17% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $30.4 million in 2021, then surged by 55.37% to $47.3 million in 2022, then surged by 46.59% to $69.3 million in 2023, then soared by 174.74% to $190.3 million in 2024, then crashed by 65.36% to $65.9 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Cash & Equivalents are $65.9 million (Q3 2025), $64.0 million (Q2 2025), and $106.2 million (Q1 2025).